98%
921
2 minutes
20
Objective: The Society for Vascular Surgery Wound, Ischemia, and foot Infection (WIfI) classification was introduced in 2014 and has been validated in multiple institutional series as a useful tool to assess the severity of chronic limb-threatening ischemia (CLTI) and predict the risk of major amputation after lower extremity revascularization (LER). The Vascular Quality Initiative (VQI) Peripheral Vascular Interventions (PVI) database captures data on wounds, ischemia, and infection, which are key components of the WIfI score, but does not provide the complete WIfI stage. The aim of this study is to validate the WIfI classification in the VQI PVI database and analyze the different combinations of components.
Methods: The VQI PVI data files (2013-2024) were reviewed for patients with CLTI with available data from which to derive WIfI scores. The characteristics of patients who underwent major amputation during follow-up were compared with those who did not. Kaplan-Meier curves were compared for major amputation, reintervention, and mortality for the various WIfI stages. Cox regression analysis was performed to assess for independent risk factors associated with major amputation.
Results: A total of 280,706 individuals underwent PVI procedures, and 130,575 presented with CLTI. WIfI stage derivation was possible for 33% (n = 42,858) of patients, 28,727 of whom had long-term follow up and were included in this study. A total of 3271 patients (11.4%) underwent major amputation after LER. Patients requiring amputation were significantly younger and more likely to be male, Hispanic, or African American compared with patients who did not undergo amputation. Patients in the amputation group were more likely to be affected by most risk factors and presented with higher WIfI stages. On Kaplan-Meier analysis, the estimates of 1-year major amputation or mortality significantly increased with each WIfI stage (stage 1, 7.7%; stage 2, 8.2%; stage 3, 14.7%; stage 4, 20.2%; P < .001). Cox regression analyses demonstrated that WIfI clinical stage (stage 2 vs 1, hazard ratio [HR], 1.17; 95% confidence interval [CI], 1.06-1.27; stage 3 vs 1, HR, 1.41; 95% CI, 1.31-1.54; stage 4 vs 1, HR, 1.69; 95% CI, 1.54-1.82) and end-stage renal disease (HR, 1.96; 95% CI, 1.8-2.14) were independently associated with major amputation or mortality.
Conclusions: In conclusion, this study validated the WIfI classification in the VQI PVI database, confirming its value in predicting major amputation and mortality in patients with CLTI. Higher WIfI stages were independently associated with increased risk of major amputation and mortality, highlighting the importance of capturing and integrating the WIfI score into all VQI modules related to treatment of peripheral artery disease.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jvs.2025.03.001 | DOI Listing |
Wounds
August 2025
Department of Nursing, Federal University of Ceará, Ceará, Brazil.
Background: Diabetic foot ulcers (DFUs) are a major clinical challenge, particularly among patients with refractory ulcers, that often lead to severe complications such as infection, amputation, and high mortality. Innovations supported by strong clinical evidence have the potential to improve healing outcomes, enhance quality of life, and reduce the economic burden on individuals and health care systems.
Objective: To describe the design of the concurrent optical and magnetic stimulation (COMS) therapy Investigational Device Exemption (IDE) study for refractory DFUs (MAVERICKS) trial.
J Cardiothorac Vasc Anesth
August 2025
Department of Anesthesiology, Zhongshan Hospital, Fudan University, Shanghai, China. Electronic address:
Objective: To compare postoperative outcomes between combined fascia iliaca compartment-sciatic nerve blockade (FICB-SNB) and monitored anesthesia care (MAC) in patients with chronic limb-threatening ischemia (CLTI) undergoing lower-extremity revascularization (LER).
Design: Retrospective matched cohort study (1:1 propensity score matching).
Setting: Single-center analysis of CLTI patients undergoing LER.
Ann Vasc Surg
September 2025
Division of Vascular Surgery, 1(st) Surgical Department, Faculty of Health Sciences, Aristotle University, Papageorgiou General Hospital, Thessaloniki, Greece.
Introduction: Nitides™ (Alvimedica, Istanbul, Turkey) is a novel polymer-free stent, which elutes Amphilimus™; a combination of sirolimus and long chain fatty acids. Aim of this prospective single-center study is to assess the efficacy and 12-months outcomes of patients with femoropopliteal arterial disease, who underwent successful angioplasty with implantation of Amphilimus™-eluting stents Nitides™.
Methods: Patients with peripheral arterial disease who underwent angioplasty of the femoropopliteal segment with DES Nitides™ from August 2021 to February 2024 were included in the study.
Circulation
September 2025
Division of Cardiology, Columbia University Irving Medical Center, New York, NY (S.A.P.).
Background: Limited treatment options exist for infrapopliteal disease in patients with chronic limb-threatening ischemia (CLTI), a condition associated with a high risk of limb loss. Interventional management of diseased infrapopliteal vessels with percutaneous transluminal angioplasty (PTA) is associated with high rates of restenosis and reintervention. In the LIFE-BTK trial, the drug-eluting resorbable scaffold (DRS) demonstrated superior 12-month efficacy compared with PTA in a selected CLTI population with predominantly noncomplex, mildly to moderately calcified lesions.
View Article and Find Full Text PDFCureus
August 2025
General Surgery, Sree Balaji Medical College and Hospital, Chennai, IND.
Gas gangrene is a rare, life-threatening infection caused mainly by and other species, such as , , , and . Other microbial pathogens also reported to cause gas gangrene are and . It is fulminant and associated with high rates of morbidity and mortality, especially in patients with underlying comorbidities such as diabetes mellitus.
View Article and Find Full Text PDF